Browse FAM212A

Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Mainly nuclear (PubMed:26607847). Relocalizes to the cytoplasm following interaction with PAK4 (PubMed:26607847).
Domain PF15342 FAM212 family
Function

Inhibitor of the serine/threonine-protein kinase PAK4 (PubMed:26607847). Acts by binding PAK4 in a substrate-like manner, inhibiting the protein kinase activity (PubMed:26607847).

> Gene Ontology
 
Biological Process GO:0021915 neural tube development
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FAM212A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FAM212A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FAM212A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1720.747
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0690.96
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2350.851
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1280.831
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.650.618
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5280.747
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.060.878
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3550.61
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2070.793
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7450.506
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9310.556
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5810.000638
> Mutation difference between responders and non-responders
 

There is no record.

Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FAM212A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FAM212A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FAM212A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FAM212A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FAM212A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FAM212A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFAM212A
Namefamily with sequence similarity 212, member A
Aliases C3orf54; chromosome 3 open reading frame 54; INKA1; Protein FAM212A
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FAM212A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.